Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $854.00 by Analysts at Piper Sandler

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price cut by equities research analysts at Piper Sandler from $855.00 to $854.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price target points to a potential upside of 28.56% from the stock’s current price.

A number of other analysts have also issued reports on REGN. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a report on Tuesday. Royal Bank Of Canada reduced their target price on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating for the company in a report on Tuesday. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, Cantor Fitzgerald lowered their price target on shares of Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating on the stock in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $787.67.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded up $1.40 during mid-day trading on Thursday, reaching $664.28. The company’s stock had a trading volume of 161,926 shares, compared to its average volume of 866,074. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $821.11. The company has a market capitalization of $70.23 billion, a P/E ratio of 16.18, a PEG ratio of 1.49 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The firm’s fifty day moving average price is $647.01 and its two-hundred day moving average price is $723.51.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the prior year, the business posted $8.22 earnings per share. The business’s quarterly revenue was up 19.0% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals will post 37.4 EPS for the current fiscal year.

Insider Activity

In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Brighton Jones LLC raised its position in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Regeneron Pharmaceuticals in the first quarter valued at $226,000. Arrowstreet Capital Limited Partnership bought a new position in Regeneron Pharmaceuticals in the second quarter valued at $3,183,000. Gabelli Funds LLC raised its position in Regeneron Pharmaceuticals by 3.0% during the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after purchasing an additional 55 shares in the last quarter. Finally, Sei Investments Co. raised its position in Regeneron Pharmaceuticals by 18.8% during the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after purchasing an additional 5,120 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.